heute kommen AFFYMETRIX-Zahlen

Beiträge: 12
Zugriffe: 1.062 / Heute: 1
Biogen kein aktueller Kurs verfügbar
heute kommen AFFYMETRIX-Zahlen HAHAHA

heute kommen AFFYMETRIX-Zahlen

24.10.00 22:02
bin vom Unternehmen 100%ig und von deren Technologie 1000%ig überzeugt.
(war gestern auf einem Mediziner-Kongress, wo mal AFFX-Chips angebetet und bestaunt wurden).

Habe aber keine AFFX, wenn die ZAhlen "Inline" sind oder darüber dann werde ich in den nächsten TAgen zulangen.

An diesen Chips führt kein Weg vorbei - weder in Forschung im Bereich Biotechnlogie, Molekularbiologie, Gentherapie - noch in der medizinischen "molekularen" Diagnostik und ERST DADURCH möglichen hochindividuellen Therapie (besonders auch bei Tumoren) und Prognose.

Wer zu den Chips noch ein Fragen hat  -ich versuche sich zu beantworten.

heute kommen AFFYMETRIX-Zahlen redcrx

Hier sind sie ...

24.10.00 22:23
Affymetrix Reports Profitable Quarter

Total Revenue Increased 89% over Q3 1999 Levels

SANTA CLARA, Calif., Oct. 24 /PRNewswire/ -- Affymetrix, Inc., (Nasdaq: AFFX) today reported results for the third quarter of 2000. For the quarter ended September 30, 2000, total revenue increased 89% to $55.8 million, up from revenue of $29.5 million for the quarter ended September 30, 1999. For the first nine months of 2000, total revenue increased 91% to $141.4 million, up from revenue of $74.1 million for the first nine months of 1999. Product sales increased 74% to $45.4 million for the quarter ended September 30, 2000 compared to $26.1 million in the comparable period of 1999. For the nine months ended September 30, 2000, product revenues were $122.2 million, an increase of 86% over the comparable period in 1999. The increase in product sales during the quarter and nine months ended September 30, 2000 over the comparable periods in 1999 was the result of increased sales of GeneChip(R) probe arrays, increased placements of instruments (primarily the GeneChip system and components, the 417 Arrayer(TM) and the 418 Scanner(TM)) and increased subscription fees earned under EasyAccess(TM) contracts. Other revenues, which include license fees, royalties and research revenue, were $10.4 million for the quarter ended September 30, 2000 and $19.2 million for the nine months ended September 30, 2000, compared to $3.4 million and $8.4 million in the corresponding periods of 1999. The increase in other revenues was attributable primarily to the expansion of licensing initiatives.

Total costs and expenses increased to $57.7 million for the quarter ended September 30, 2000, from $36.0 million for the comparable period in 1999. For the first nine months of 2000, total costs and expenses increased to $158.7 million, compared to $97.6 million for the same period in 1999. The increase in operating expenses for the three and nine month periods ended September 30, 2000 compared to the respective periods in 1999, resulted primarily from the Company's expansion of commercial activities and increased legal costs arising from ongoing patent litigation.

The Company reported net income attributable to common stockholders of $0.3 million, or $0.01 of basic earnings per share for the quarter ended September 30, 2000, compared to a net loss attributable to common stockholders of $5.8 million, or $0.11 of basic earnings per share, for the comparable period in 1999.

"The third quarter was a tremendous period of growth and progress for Affymetrix," said Susan E. Siegel, President of Affymetrix. "We will continue strategic initiatives such as those made during the third quarter in order to position Affymetrix for continued growth."

During the third quarter, Affymetrix continued its market expansion by entering into many GeneChip array supply agreements with pharmaceutical, biotechnology and academic customers, further demonstrating the continued demand from the genomics community for the Company's technology. At the end of the quarter, Affymetrix had sold over 350 GeneChip systems and over 550 Affymetrix spotted Arrayers and Scanners. Notable in the quarter were EasyAccess Silver agreements with the Janssen Research Foundation (JRF) and The R.W. Johnson Pharmaceutical Research Institute (PRI), both members of the Johnson & Johnson family of companies and Schering AG of Germany. The company also signed BiotechAccess(TM) agreements with deCODE genetics and Exelixis, Inc. as well as numerous AcademicAccess(TM) supply agreements, bringing the total number of participating institutions to over 125 at the end of the quarter.

In addition to signing new supply agreements in the third quarter of 2000, Affymetrix also entered into a partnership with the Cystic Fibrosis Foundation to develop a custom GeneChip expression array based on Pseudomonas aeruginosa, the most common cause of respiratory infections in cystic fibrosis patients. It is anticipated that these custom arrays will be developed for use by cystic fibrosis researchers worldwide to further study the genome and develop new treatments to ease the suffering of those with cystic fibrosis.

Affymetrix also continued to enable the DNA array field in the quarter through its licensing program. Notable in the quarter was a commercial use license granted to Takara Shuzo Co., Ltd. that allows Takara to manufacture, use and sell low and medium density pre-spotted DNA arrays. At the end of the quarter, Affymetrix had over 20 licensees.

During the quarter, Affymetrix also made several announcements of strategic importance. First was the agreement to acquire Neomorphic, Inc., a privately held computational genomics company known for its best in class ability to analyze, assemble and annotate multiple sources of raw sequence information. This acquisition will strengthen Affymetrix by enhancing the company's ability to offer scientists an unparalleled view of the genome, along with powerful new tools to interpret and understand the assembled genomic information. Also during the quarter, Affymetrix formed a new genomics subsidiary called Perlegen Sciences, Inc. Perlegen Sciences will focus on revolutionizing biological and pharmaceutical research by using the latest technology from Affymetrix to scan 50 genomes and identify the millions of genetic variations between individuals -- a technological feat that is now cost-effective using Affymetrix technology. Finally, Affymetrix, in cooperation with SmithKline Beecham, Merck & Co., the National Institutes of Health, the National Cancer Institute and the Wellcome Trust, announced a public-private initiative to provide $58 million over the next six months to decipher the mouse sequence, an important model organism for biomedical research. As a result of this effort, it is anticipated that the mouse sequence will be broadly available and Affymetrix will use the sequence to provide new chips to ensure that all researchers have access to tools that allow for further medical breakthroughs. These and other data will be extremely valuable for their link to human health and disease and Affymetrix intends to make this information broadly available to researchers worldwide via GeneChip probe arrays.

Investors may listen to Affymetrix' management discuss this announcement by dialing domestic: 888-732-8927; international: 212-346-6409; passcode -- 1959 on Tuesday, October 24, from 2:00 - 3:00 p.m. PDT. A replay of this call will be available for 4 days, domestic: 800-633-8284; international: 858-812-6440; reservation number -- 16616321. To access a Webcast of the conference call, go to www.affymetrix.com/news/index.html and then click on the "Press Releases" tab.

Affymetrix is a leader in developing and commercializing systems to acquire, analyze and manage complex genetic information in order to improve the quality of life. The Company's GeneChip system consists of disposable DNA probe arrays containing gene sequences on a chip, reagents for use with the probe arrays, a scanner and other instruments to process the probe arrays and software to analyze and manage genetic information. The Company's spotted array system enables individual researchers to create and analyze custom microarrays on an easy-to-use, cost-efficient platform. Additional information on Affymetrix and GeneChip technology can be found at www.affymetrix.com.

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, uncertainties relating to technological approaches, product development, manufacturing, market acceptance, personnel retention, equity dilution, uncertainties related to the ability to realize benefits from acquisitions, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Annual Report on Form 10-K for the year ended December 31, 1999 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

NOTE: Affymetrix, GeneChip and the Affymetrix logo are registered trademarks used by Affymetrix, Inc.

                              AFFYMETRIX, INC.
                  (In thousands, except per share amounts)

                                    Three Months Ended   Nine Months Ended
                                      September 30,         September 30,
                                     2000       1999        2000      1999

    Product                       $45,372    $26,137    $122,227   $65,713
    Research                        1,855      2,420       4,729     6,736
    License fees and royalties      8,542        962      14,455     1,698
     Total revenue                 55,769     29,519     141,411    74,147

   Costs and expenses:
    Cost of product revenue        18,400     11,578      49,117    28,718
    Research and development       13,730     10,477      38,890    31,128
    Selling, general and
     administrative                25,533     13,908      68,334    37,752
    Merger acquisition costs           --         --       2,395        --
     Total costs and expenses      57,663     35,963     158,736    97,598

   Loss from operations           (1,894)    (6,444)    (17,325)  (23,451)
   Interest income, net             2,189      1,105       5,259     3,496
   Net income (loss)                  295    (5,339)    (12,066)  (19,955)
   Preferred stock dividends           --      (429)          --   (2,055)

   Net income (loss) attributable
   to common stockholders            $295   $(5,768)   $(12,066) $(22,010)

   Basic earnings (loss)
    per common share                 $.01    $(0.11)     $(0.22)   $(0.44)

   Weighted-average shares
    used in computing basic
    earnings (loss)
    per common share               55,319     51,914      54,928    50,255

   Diluted earnings (loss)
    per common share               $ 0.00    $(0.11)     $(0.22)   $(0.44)

   Weighted-average shares
    used in computing diluted
    earnings (loss)
    per common share               61,145     51,914      54,928    50,255

Note: Certain prior year balances have been reclassified to conform with the current year presentations.

                              AFFYMETRIX, INC.
                               (In thousands)

                                           September 30,    December 31,
                                                2000           1999
                                           (Unaudited)        (Note)

   Current assets:
    Cash and cash equivalents                   $3,770        $12,677
    Available-for-sale securities              425,292        213,763
    Accounts receivable                         47,697         24,646
    Inventories                                 17,599         12,792
    Other current assets                         2,893          4,159
     Total current assets                      497,251        268,037
   Net property and equipment                   52,730         40,775
   Acquired technology rights                   10,224          8,965
   Notes receivable from stockholders            1,319          1,074
   Other assets                                 47,759          7,736
                                              $609,283       $326,587


   Current liabilities:
    Accounts payable and
     accrued liabilities                       $41,534        $29,926
    Deferred revenue                            19,627          6,468
    Current portion of capital
     lease obligation                               68            261
      Total current liabilities                 61,229         36,655
   Obligation to Beckman Coulter, Inc.           5,000          5,000
   Convertible subordinated notes              375,000        150,000
   Common stock purchase rights                  3,000          3,000
   Stockholders' equity:
    Common stock                                   555            543
    Additional paid-in-capital                 270,485        256,467
    Accumulated deficit                      (136,269)      (124,203)
    Other                                       30,283          (875)
     Total stockholders' equity                165,054        131,932
                                              $609,283       $326,587

Note: The balance sheet at December 31, 1999 has been derived from the supplemental audited consolidated financial statements at that date included in the Company's Form 8-K filed on April 7, 2000, but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

heute kommen AFFYMETRIX-Zahlen Sherlock

Mannohmann, bin ich froh, habe schon gezittert.

24.10.00 22:33
heute kommen AFFYMETRIX-Zahlen HAHAHA


24.10.00 22:43
also, wenn ich die Zahlen richtig interpretiere, dann kann es nur eines geben: kaufen - abe wartet, bis ich gekauft habe !!!!!!!!!!!!!!!!!!!!!!!!!!

schätze, ich werde mir einen Call zu legen - mit wirklich langer Laufzeit !

heute kommen AFFYMETRIX-Zahlen Sherlock

Ich habe den Eindruck, Affymetrix ist einer der

24.10.00 22:51
wenigen Biotechwerte, bei denen die Zahlen eine Rolle spielen. Bei allen anderen (außer Amgen, Biogen usw.) ist die Phantasie die treibende Kraft, AFFX hat harte Fakten auf den Tisch gelegt!

heute kommen AFFYMETRIX-Zahlen HAHAHA

nachbörslich +12% o.T.

24.10.00 22:58
heute kommen AFFYMETRIX-Zahlen HAHAHA

kacke - ich feige Sau traute nicht vor den Zahlen

24.10.00 22:58
zu kaufen
heute kommen AFFYMETRIX-Zahlen Sherlock

Hi HAHAHA, ich meine, vor Zahlen zu kaufen gleicht

24.10.00 23:10
einem Glücksspiel. Ich finde es nicht feige, sondern clever. Wenn da -1 Cent im Ergebnis gestanden hätte, dann würde das jetzt anders ausschauen. Ich denke mal, daß man jetzt ein zwei Tage warten sollte und dann getrost einsteigen kann. Das Vertrauen ist erst mal wieder da. Evtl. sollte man die Patentstreitigkeiten noch beobachten.

Der ARIVA.DE Newsletter
Bleiben Sie informiert mit dem
wöchentlichen Marktüberblick
Ich möchte Benachrichtigungen von ARIVA.DE erhalten.
Ja, ich habe die Datenschutzhinweise gelesen und akzeptiert (Pflichtfeld).
heute kommen AFFYMETRIX-Zahlen HAHAHA


24.10.00 23:22

Jungs bringt mich wieder auf den Teppich.

Ihr wisst - ich bin bezüglich Biotech immer skeptisch (oft ZU skeptisch).
Aber allerspätestens seit gestern (Kongress: Schwerpunkt Gentherapie, Molekulare Medizin, Wien) bin ich nahezu gefesselt von dieser Chiptechnologie, deren Einsatzmöglichkeiten und wie in wenigen Jahren völlig neue (höchst individuelle !!!) Therapiemassnahmen möglich sein werden.

Und das ganze zunächst schon OHNE Gentherapie und Firlefanz von neuen Wirkstoffen - nein schon den derzeitig verfügbaren Medikamenten.

Ich bringen ein Beispiel:
(wurde auch schon in etwa so publiziert):

grosszelliger B-Zelltumor (bösartiger Tumor aus Lymphozyten - Leukämieart).

Mit dem AFFX-Chip kann man in EINEM Untersuchungsgang die Aktiviät von 60000
Genen untersuchen !!!

Sprich. man kann binnen weniger Tage sagen: dieser Tumor produziert dieses und jenes Enzym, trägt diesen und jenen Rezeptor an der Zelloberfläche, hat dieses Zytoskelett.

Bisher musste man für JEDE dieser Aussagen lange zeitaufwendige Tests machen, um an diese Infos zu gelangen.

Mit diesen Chips kann man theoretisch zu 60000 Genen (und damit zu 60000 EIgenschaften der Tumorzellen) die Info bekommen.

Klarerweise werden dann in der medizinischen Anwendung (je nach Tumor) nur 3, 4, 10, 20 oder 100 (??) wirklich relevant für die Therapie und Prognose sein.

Zur Zeit werden bei Brustkrebs gerade mal 4 Merkmale untersucht (Östrogen- und, Progesteronrezeptor, HerbB2 und manchmal auch p53.

Das ist für eine individuelle Therapie klarereise ZUWENIG.

In Zukunft wird man dann die 60000 Gene von Tumoren vergleichen mit der Aktivät der selben 60000 Gene von normalen Zellen.

Und dabei wird es MEHR als nur 3 oder 4 Unterschiede geben.

1,Diese Chips werden der molekularbiologischen Forschung einen GIGANTISCHEN Beschleunigiungsschub geben.

2, Man wird eine UNMENGE an neuen Daten bekommen (Lion strong buy ?) WELCHE Gene aktiv sind - im Vergleich: kranke Zelle - gesunde Zelle.

3. Kein Forschungslabor, dass international bstehen will, wird ohne diese Chips arbeiten können.

4. Eine Revolution in diagnostischen Labors steht unmittelbar bevor:
  medizinische, gerichtliche, private,.....

5. eine hochindividuelle Therapie wird möglich sein:

 Tumoren werden dann nicht mehr wie zB folgt klassifiziert: "Groszelliges B-Zelllymphom"  - sondern anhand der Aktivät der 60000 Gene - und ebenso verfeinert kann dann die Therapie angewendet werden.

6. Neue Gene werden entdeckt werden (durch spezielle "Oligo-chips").

7. Funktion  und Bedeutung von derzteit zwar bekannten Genen werden genau erforscht werden können - von denen man bisher nur wusste, dass es sie gibt.

Mannoman - das ist eine spannende Entwicklung !!!!!!!!!!!!

Achja: Genescan: wird vom AFFX-Aufschwung sicher mitprofitieren.

Ohne Einstieg in die Medizin -abe würde ich AFFX KLAR bevorzugen.

Vergleich:   AFFX-Genscan
heute kommen AFFYMETRIX-Zahlen Sherlock

Denke ich auch, allerdings, wenn ich einen

24.10.00 23:27
zusätzlichen Genechipwert ins Depot nehmen würde, würde ich mich wahrscheinlich für Sequenom entscheiden. Die scheinen mit ihren MassArrays auch tollen Erfolg zu haben.

heute kommen AFFYMETRIX-Zahlen HAHAHA

AFFY-KGV2001 ? das kann meiner Meinung nicht hoch

25.10.00 00:12
verzeiht mir die undeutliche Ausdrucksweise, schätze aber, das die Prognosen
für AFFX 2001 und 2002 angehoben werden müssen.

Bin mal gespannt auf Analystenstimmen in den nächsten Tagen - als Reaktion auf diese Zahlen.

heute kommen AFFYMETRIX-Zahlen HAHAHA

nachbörslich aktuell +15%

so und jetzt ist Schluss - sonst werde ich hier noch zum Alleinunterhalter.


Börsenforum - Gesamtforum - Antwort einfügen - zum ersten Beitrag springen

Neueste Beiträge aus dem Biogen Forum